Newron Pharmaceuticals Spa Stock Earnings Per Share
| NWRN Stock | CHF 10.60 0.16 1.53% |
Newron Pharmaceuticals SpA fundamentals help investors to digest information that contributes to Newron Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Newron Stock. The fundamental analysis module provides a way to measure Newron Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Newron Pharmaceuticals stock.
Newron |
Newron Pharmaceuticals SpA Company Earnings Per Share Analysis
Newron Pharmaceuticals' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Newron Pharmaceuticals Earnings Per Share | (0.85) X |
Most of Newron Pharmaceuticals' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Newron Pharmaceuticals SpA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, Newron Pharmaceuticals SpA has an Earnings Per Share of -0.85 times. This is 110.16% lower than that of the Healthcare sector and 82.25% lower than that of the Biotechnology industry. The earnings per share for all Switzerland stocks is 127.24% higher than that of the company.
Newron Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Newron Pharmaceuticals' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Newron Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Newron Pharmaceuticals by comparing valuation metrics of similar companies.Newron Pharmaceuticals is currently under evaluation in earnings per share category among related companies.
Newron Fundamentals
| Return On Equity | -8.4 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (2.44) % | |||
| Operating Margin | (1.84) % | |||
| Current Valuation | 32.84 M | |||
| Shares Outstanding | 17.85 M | |||
| Shares Owned By Insiders | 4.96 % | |||
| Shares Owned By Institutions | 7.28 % | |||
| Price To Earning | (11.88) X | |||
| Price To Book | 7.98 X | |||
| Price To Sales | 3.95 X | |||
| Revenue | 5.76 M | |||
| Gross Profit | 5.76 M | |||
| EBITDA | (11.76 M) | |||
| Net Income | (14.9 M) | |||
| Cash And Equivalents | 58.99 M | |||
| Cash Per Share | 3.31 X | |||
| Total Debt | 42.93 M | |||
| Debt To Equity | 0.70 % | |||
| Current Ratio | 13.90 X | |||
| Book Value Per Share | (0.29) X | |||
| Cash Flow From Operations | (11.45 M) | |||
| Earnings Per Share | (0.85) X | |||
| Target Price | 4.35 | |||
| Number Of Employees | 25 | |||
| Beta | 1.11 | |||
| Market Capitalization | 81.91 M | |||
| Total Asset | 50.49 M | |||
| Z Score | 0.6 | |||
| Net Asset | 50.49 M |
About Newron Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Newron Pharmaceuticals SpA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Newron Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Newron Pharmaceuticals SpA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| C | Citigroup | |
| CRM | Salesforce | |
| MSFT | Microsoft |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Newron Pharmaceuticals SpA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Newron Stock analysis
When running Newron Pharmaceuticals' price analysis, check to measure Newron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Newron Pharmaceuticals is operating at the current time. Most of Newron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Newron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Newron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Newron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |